These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9269551)

  • 41. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
    Fallick ML; McDermott DF; LaRock D; Long JP; Atkins MB
    J Urol; 1997 Nov; 158(5):1691-5. PubMed ID: 9334580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal cell cancer: is there long-term survival advantage from cytokine treatment?
    Oliver RT
    Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400
    [No Abstract]   [Full Text] [Related]  

  • 43. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
    Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
    N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
    Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
    Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 50. Nephrectomy for metastatic renal-cell cancer.
    Bolger G
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11932483
    [No Abstract]   [Full Text] [Related]  

  • 51. Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG PET despite radiographic evidence suggesting persistent tumor.
    Mankoff DA; Thompson JA; Gold P; Eary JF; Guinee DG; Samlowski WE
    AJR Am J Roentgenol; 1997 Oct; 169(4):1049-50. PubMed ID: 9308463
    [No Abstract]   [Full Text] [Related]  

  • 52. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
    Oliver RT
    Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal cancer immunotherapy: a ray of hope or regression to the mean?
    Stadler W
    Cancer Invest; 2000; 18(5):490-1. PubMed ID: 10834033
    [No Abstract]   [Full Text] [Related]  

  • 59. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
    Atzpodien J; Reitz M
    Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Renal cell carcinoma with colon metastases: an infrequent site for metastases].
    Valdespino-Castillo VE; Ruiz-Jaime A
    Cir Cir; 2008; 76(4):339-42. PubMed ID: 18778546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.